γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine m...

Descripción completa

Detalles Bibliográficos
Autores principales: Frieling, Jeremy S., Tordesillas, Leticia, Bustos, Xiomar E., Ramello, Maria Cecilia, Bishop, Ryan T., Cianne, Junior E., Snedal, Sebastian A., Li, Tao, Lo, Chen Hao, de la Iglesia, Janis, Roselli, Emiliano, Benzaïd, Ismahène, Wang, Xuefeng, Kim, Youngchul, Lynch, Conor C., Abate-Daga, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156127/
https://www.ncbi.nlm.nih.gov/pubmed/37134157
http://dx.doi.org/10.1126/sciadv.adf0108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156127/
https://www.ncbi.nlm.nih.gov/pubmed/37134157
http://dx.doi.org/10.1126/sciadv.adf0108

Ejemplares similares